UROLOGY

VOLUME 57, JANUARY TO JUNE 2001

Pages	Issue	Pages	Issue
1–210	January	4A-1–4A-248	April Supplement
211–398	February	847–1012	May
399–590	March	1013–1208	June
591–846	April	6A-1–6A-132	June Supplement

AUTHOR INDEX

Abbou, C.-C., 306, 617, 883
Abele, S.T., 6A-67
Aben, K.K.H., 266
Agerter, D.C., 599, 604
Akasaka, S., 579
Akimoto, M., 579
Akino, H., 257
Alberts, S.R., 4A-188
Alcser, K.H., 91
Aldasouqi, S., 554
Aldigé, C., 4A-52
Ali, A., 176
Ali, I.U., 4A-143
Ali, N.I., 906
Alsikafi, N.F., 296, 355
Althof, S.E., 960
Altınok, D., 623
Altschuler, M.D., 286
Alvarez-Horine, S., 6A-62
An, C.D., 975
An, G., 4A-164
Anafarta, K., 1184
Andankar, M.G., 906
Anders, K.H., 554
Anderson, B., 556
Angeli, A., 176
Anglade, R.E., 800
Angulo, J., 585
Ankem, M., 973
Ankem, M.K., 791, 800
Antolín Juárez, F.M., 685
Antunes, E., 816
Aoki, Y., 701, 721
Apostolidis, A., 966
Appell, R.A., 668, 911
Arai, Y., 701, 721
Arakawa, S., 188
Arnold, T.V., 783
Aronson, W.J., 476
Assimos, D.G., 161
Atsu, N., 542
Austin, P.F., 338
Autier, P., 712
Ayala, G., 8

Bacus, J., 4A-129
Badia, X., 71
Baffoe-Bonnie, A.B., 97
Baglietto, L., 97
Bahn, D., 518
Bailey-Wilson, J.E., 97
Bajpai, M., 547
Bales, G.T., 45
Ball, R.Y., 169
Ball, T.P., Jr, 1162
Banks, K.L.W., 365
Banner, M.P., 660
Barette, M., 712
Barone, J.G., 791
Barrett, D.M., 1051
Barry, M.J., 1085
Bartels, P., 4A-129
Bartsch, G., 1100
Başar, H., 623
Başar, M.M., 623
Baseman, A.G., 60
Basharkhah, A., 66
Basler, J.W., 495
Batislam, E., 623
Batler, R.A., 798, 1163
Batuello, J.T., 481
Baudiere, M., 146
Baumgartner, R., 690
Beaty, T.H., 97
Becker, A.J., 193
Beiko, D.T., 1082
Beitz, J., 4A-213
Bejany, D.E., 670
Belldegrun, A., 4A-95
Bellin, P.B., 1178
Benaim, E.A., 170
Benedict, W.F., 852
Bennett, C.J., 960
Bennett, C.L., 275, 727
Bergan, R.C., 4A-77
Bergstralh, E.J., 1033
Berkel, H.J., 471
Berkman, S., 1178
Bernheim, B.D., 866
Bernhofer, G., 567
Bernsen, R.M.D., 1093
Bernués, M., 986
Beuchert, P., 342
Bevers, R.F.M., 1133
Bishoff, J.T., 976
Bishop, C.W., 4A-81
Bjorling, D.E., 6A-40
Black, L.D., 530
Blaivas, J.G., 1145
Blander, D.S., 660
Blanker, M.H., 763, 1093
Bloom, D.A., 843
Blute, M.L., 1033, 4A-188
Boccuzzi, A., 176
Bohnen, A.M., 763, 1093
Bono, A.V., 117
Boon, T.A., 695, 1133
Boone, C.W., 4A-46, 4A-129
Boone, T.B., 239, 365, 658, 1051
Borkon, W.D., 960
Borth, C.S., 1082
Bosch, J.L.H.R., 763, 1093
Bosland, M.C., 4A-202
Bovio, S., 176
Boykin, W.H., 960
Brady, M.S., 633
Brake, M., 900
Bree, R.L., 1128
Brendler, C.B., 296
Brensinger, C., 6A-67
Brock, G., 536
Broderick, G.A., 626, 660
Broecker, B., 1178
Broecker, B.H., 1178
Brooks, J.D., 4A-100
Brössner, C., 389
Brown, J.M., 611
Brown, M.P., 573
Brown, R.M., 60
Bruskewitz, R., 1073
Burnett, A.L., 209
Burton, M.P., 976
Butler, W.M., 524
Byers, R., 733

Caballín, M.R., 986
Cadeddu, J.A., 448, 554, 562
Cain, M.P., 168, 338, 554
Cao, B., 826
Cappia, S., 176
Carballido, J., 71
Carducci, M., 1033, 4A-81
Caridi, J., 800
Carmignani, G., 319
Carroll, P., 217, 225
Carroll, P.R., 499, 591, 599, 604, 4A-200
Carson, P.L., 1128
Carter, H.B., 925, 1013, 1112
Carter, S.K., 4A-77
Cartwright, P.C., 1158
Casale, A.J., 338
Catalona, W.J., 97, 491
Cayan, S., 328, 530
Cecconi, P.P., 866
Cendron, M., 1156
Cespedes, R.D., 40, 396
Chai, T., 6A-9
Chai, T.C., 207, 396
Chan, D.W., 707
Chan, D.Y., 360, 448, 774
Chancellor, M.B., 826
Chandrasekharam, V.V.S.S., 547
Chang, B., 800
Chang, B.S., 1063
Chang, S.S., 801, 1179
Chang, Y.-H., 650
Chapman, J.D., 821
Chen, C., 769
Chen, K.-K., 650
Chen, P.-M., 650
Cheng, W.S., 206
Cherullo, E.E., 365
Cheung, R., 286
Chin, J.L., 230
Chinn, D.O., 518
Chitale, S.V., 169
Chmiel, J.S., 275
Choi, E., 769
Choi, J., 151
Chopin, D.K., 306, 617, 883
Choudhury, M.S., 183
Chow, N.-H., 837
Chu, W., 199
Ciancio, S.J., 239, 554
Civantos, F., 949
Clark, L.C., 4A-185
Clark, P.E., 252, 281
Clark, S.B., 281
Clayman, R.V., 643
Coffey, D.S., 4A-31
Cohen, J.K., 34
Cohen, M., 800
Cohen, P., 573
Coley, C., 217, 225
Collick, C., 562
Collins, G.N., 1098
Collins, S.M., 554
Colombel, M., 306
Coltman, C.A., 4A-230
Comeri, G., 117
Committee on Publication Ethics (COPE), 3
Conlin, M., 168
Cook, T.J., 1073
Cooney, K.A., 91
Cooper, C.S., 347, 351
Cooper, V.L., 151
Corey, E., 611
Correa, H., 554
Corvin, S., 690
Corwin, T.S., 554, 562
Cosciani-Cunico, S., 117
Costello, A.J., 4A-182
Crawford, E.D., 481, 727
Crisci, A., 78
Cronin, K.A., 4A-220
Crowell, J.A., 4A-46
Crowley, J.D., 976
Cuellar, D.C., 138
Cuevas, P., 585
Cvetkovic, D., 821

Dagher, R., 975
Dal-Ré, R., 71
Dalrymple, N.C., 976
D'Amico, A.V., 286
Daniltchenko, D., 675
Davidson, S.D., 183

© 2001, Elsevier Science Inc.
ALL RIGHTS RESERVED

0090-4295/01/$20.00
PII S0090-4295(01)01199-2

Davis, J.W., 555
Davis, M.M., 168
Day, M.L., 860
De Antoni, P., 78
Debois, H., 617, 883
De Dominicis, C., 1059
de Gier, R.P.E., 793
De Giuli, P., 176
de Groat, W.C., 826
Deguchi, T., 17
de la Rosette, J.J.M.C.H., 705, 914
Delk, J.R., 142
DeMarco, R.T., 168
De Marzo, A.M., 4A-39, 4A-103
DeMasi, V., 727
De Nucci, G., 816
De Nunzio, C., 1059
Derogee, M., 1133
De Rose, A.F., 319
De Wachter, S., 655
DeWeese, T.L., 4A-39, 4A-137
Diamandis, E.P., 471
Diamanti, L., 117
Diamond, S.M., 800, 973
Dicker, A.P., 821
Dinney, C.P.N., 852
Diokno, A.C., 1044
Djavan, B., 66
Dmochowski, R.R., 382
Do, T.M., 1121
Doerr, K.M., 91
Donzella, J.G., 524
Dorey, F., 476
Dorey, F.J., 999
Doshi, N.M., 800
Dreicer, R., 281
Dugas, G.R., 230
Dunton, N.G., 454

Eckhardt, M.D., 695
Edmondson, J.W., 554
Egevad, L., 291
Egozcue, J., 986
Ehle, J.J., 347
Eisenberger, M.A., 1033
Ekici, S., 323
Eland, I.A., 970
Elbers, F.H., 1133
Eller, D., 1178
Elliott, D.S., 365, 1051
Ellsworth, P.I., 1156
Endrizzi, J., 733
Epstein, J.I., 707, 1033, 1112, 4A-191
Erbersdobler, A., 486
Erdemir, F., 328
Erdoğru, T., 758
Ergen, A., 323, 542
Erickson, D.R., 6A-9, 6A-15
ESECI-98 Group, 71
Espinosa, E.A., 866
Evans, D.H., 670

Faerber, G.J., 639
Fagelman, A., 1141
Fagelman, E., 407, 1141
Fair, W.R., 4A-200
Fakhari, M., 66
Fan, F.S., 650
Faro, R., 816
Feldman, H.A., 930
Ferlise, V., 791
Ferlise, V.J., 800
Fernández, A., 585
Feroz, F., 1145
Ferri, M., 230
Fiaccavento, G., 117
Fine, R., 275
FinnBladder Group, 680
Fisch, B.M., 955
Fisch, H., 151
Flanders, S.C., 499
Fleisher, L.A., 925
Fleshner, N.E., 4A-90
Fontana, D., 176
Forrest, J.B., 6A-26
Fowlkes, J.B., 1128
Franke, M., 717
Franks, M.E., 551
Fraundorfer, M.R., 454
Freedland, S.J., 476
Freedman, L.S., 4A-220
Fregonesi, A., 816
Frimberger, D., 690
Fullerton, S.A., 183
Fung, L.C.T., 550, 1178
Furuya, S., 270

Gabancho, S., 585
Galbreath, R.W., 524
Gallentine, M.L., 40, 788
Gamito, E.J., 481
Garbagnati, F., 78
Garcia, F.U., 34
Garderet, L., 168
Gattegno, B., 168
Gatti, J., 1178
Gatti, J.M., 1178
Gaudin, P.B., 801, 1179
Gazi, M., 791
Gazi, M.A., 800
Gearhart, J.P., 349, 774, 910
Geffriaud-Ricouard, C., 459
Geisinger, M.A., 21
Gelabert, A., 986
Gelbard, M.K., 757
George, D.J., 122
Gerber, G.S., 45, 296, 355
Gerhards, S., 675
Gershbaum, M.D., 342
Giberti, C., 666
Giglio, M., 319
Gill, R., 889
Gilling, P.J., 454
Gilroy, A.M., 1178
Gingrich, J.R., 439
Ginsberg, P.C., 889, 1078
Girman, C.J., 1087
Glazier, D.B., 791
Gluckman, E., 168
Goel, A., 644
Goessl, C., 1006
Gohma, M., 1051
Goldberg, J.D., 742
Goldstein, I., 301
Golomb, J., 159, 946
Gomella, L.G., 769
Gomes, C.M., 262
Gonzalez, C.M., 1163
Goodman, J., 146
Goodman, P., 4A-230
Gotoh, A., 188
Gousse, A.E., 670
Graefen, M., 486
Green, A.E., 60
Greenberg, R.E., 821
Grimaldi, G., 633
Grivegnée, A.R., 712
Grizzle, W.E., 4A-220
Groeneveld, F.P.M.J., 763, 1093
Grossfeld, G.D., 394, 599, 604
Grossman, H.B., 847
Grouse, L.H., 4A-154
Groutz, A., 159, 1145
Gsur, A., 567
Guazzieri, S., 117
Guillé, F., 628
Guiraud, P., 628
Gupta, D.K., 547
Gupta, N.P., 644
Güray, M., 895
Gutiérrez Baños, J.L., 685
Guyton, J.L., 439

Hackmann, K., 122
Hafez, K.S., 252
Hahn, R.G., 1081
Haidinger, G., 567
Haitel, A., 567
Hammerer, P., 486
Han, K.-R., 973
Han, M., 481, 707, 1033
Hanks, G.E., 821
Hanlon, A.L., 821
Hanna, M.K., 783
Hanno, P., 6A-1, 6A-2, 6A-82
Hara, I., 188
Hara, S., 188
Hardie, W.R., 230
Hardy, C., 6A-67
Hargreave, T.B., 459
Harik, M., 66
Harkaway, R.C., 889, 1078
Harris, C., 262
Hartanto, V.H., 800, 973
Hartmann, U., 193
Hartung, R., 878
Harvie, S., 199
Hashizume, K., 975
Hatzichristou, D.G., 966
Hatzimouratidis, K., 966
Hauptmann, S., 675
Hautmann, R.E., 486
Hautmann, S.H., 486
Hawke, C., 949
Hawtrey, C.E., 347
Hayashi, Y., 1151
Heeringa, S.G., 91
Heicappell, R., 1006
Heldeweg, E.A., 1068
Hellström, P., 30
Hellstrom, W.J.G., 757
Hemal, A.K., 644
Henderson, D., 4A-95
Henke, C.J., 499
Henke, R.-P., 486
Hensle, T.W., 151
Hernady, T., 389
Herndon, C.D.A., 1178
Herr, H.W., 59
Herzog, A.R., 1044
Hess, D.L., 999
Heston, W.D.W., 801, 1179
Higashihara, E., 936
Higley, H.R., 4A-46
Hilton, S., 168
Hinder, R.A., 1025
Hines, J., 342
Hinteregger, S., 567
Hintz, B.L., 975
Hirsch, I.H., 769
Ho, M., 199
Hoenig, D.M., 34
Hofstetter, A., 690
Hollabaugh, R.S., Jr, 382
Hollenbeck, B.K., 394, 639
Hollowell, C.M.P., 45
Holtgrewe, H.L., 1073
Homma, Y., 811
Hop, W.C.J., 763
Horak, I., 4A-77
Horniger, W., 1100
Horsch, R., 900
Hosaka, Y., 811
Hoznek, A., 617, 883
Hrebinko, R.L., Jr, 551
Hricak, H., 599, 604
Hruszkewycz, A.M., 4A-137, 4A-148, 4A-194
Hsu, C.C., 365
Hsu, T.H., 1166
Huang, J.-K., 872
Huang, J.-S., 872
Huang, W.-C., 872
Huard, J., 826
Huet, F., 712
Huland, H., 486
Hulsbergen-van de Kaa, C.A., 914
Hultgren, S.J., 6A-56
Hunt, T.L., 1044
Husmann, D.A., 545
Hwang, T.K., 371

Ichioka, K., 701
Interstitial Cystitis Data Base Study Group, 6A-67
Ioannides, E., 966
Iori, F., 1059
Iqbal, N., 554
Irani, J., 617, 883
Irwin, R.J., 142
Ishigooka, M., 207
Ishihara, S., 17
Ishiwata, S., 811
Issa, M.M., 26
Italian PROSIT Study Group, 117
Ito, M., 17

Itoh, N., 270
Iverson, A.J., 976

Jaffe, J.S., 889, 1078
Jarow, J.P., 626
Jarrett, T.W., 448
Javidan, J., 169, 975
Jeffs, R.D., 774
Jeong, G.W., 1189
Jewett, M.A.S., 199
Jiaan, B.-P., 872
Johnin, K., 975
Johnson, G.B., 183
Johnson, J.E., 168
Jonas, U., 193, 414
Jonges, T.G.N., 1133
Jung, I., 434
Jung, K., 675

Kaasinen, E., 680
Kadioğlu, A., 328, 758
Kadmon, D., 8, 211
Kaefer, M., 338
Kagan, A.R., 975, 1121
Kakehi, Y., 993
Kalish, L.A., 930
Kameyama, S., 811
Kamidono, S., 188
Kanamaru, H., 257
Kanamori, Y., 975
Kandirali, E., 328
Kang, H.K., 1189
Kantoff, P.W., 122, 4A-86
Kao, P.-F., 246
Kaplan, S.A., 1073
Kapp, D.S., 800
Kataoka, A., 975
Kato, I., 4A-202
Kato, M., 936
Katz, D.S., 342
Katz, G., 112
Katz, J., 633
Kaul, S., 906
Kauppinen, R., 680
Kavolius, J.P., 633
Kavoussi, L.R., 360, 448
Kawarasaki, H., 975
Keay, S., 6A-9, 6A-22
Keegan, P., 4A-216
Keller, H., 900
Kelloff, G.J., 4A-46, 4A-220
Kempuraj, D., 6A-47
Kendi, S., 323, 542
Kennedy, A., 4A-86
Kennett, K.M., 454
Keoleian, C.M., 169
Kernen, K., 8
Khorsandi, M., 34
Kidwell, R., 786
Kiemeney, L.A., 97
Kiemeney, L.A.L.M., 266, 747
Kim, E.D., 211, 921, 1016
Kim, F.J., 1160
Kim, H.J., 1189
Kim, H.L., 45, 1063
Kim, J.C., 371
Kim, N.W., 4A-148
Kim, S.C., 798
King, C., 800
Kiratli, B.J., 127
Kırkalı, Z., 895
Kirsch, A., 1178
Kirsch, A.J., 153, 1178
Kitamura, T., 811
Kitano, Y., 975
Klein, E.A., 281, 4A-4, 4A-171, 4A-230
Klingler, H.C., 1025
Klingler, P.J., 1025
Klumpp, D.J., 556
Knapp, W.H., 193
Knight, S.J., 275
Knoll, L.D., 753
Knüchel, R., 690
Kobayashi, S., 17
Koenig, F., 675
Kogan, B.A., 843
Kogan, S.J., 157
Kohri, K., 1151
Koizumi, S., 975
Kojima, M., 376
Kojima, Y., 1151
Koki, A., 4A-73
Köksal, T., 758
Kolettis, P.N., 1138
Kolvenbag, G., 4A-64
Konety, B., 168
Kong, C., 981
Konno, S., 183
Kopelovich, L., 4A-46
Kouril, M., 4A-230
Kozlowski, P.M., 365
Kranse, R., 83
Krause, H., 1006
Kreder, K., 414
Kreder, K.J., 422
Krege, S., 55
Kriegmair, M., 690
Krongrad, A., 504, 510
Kuber, W., 389
Kucuk, O., 4A-90
Kumar, R., 644
Kumon, H., 826
Kurhanewicz, J., 4A-124
Kusek, J.W., 6A-67, 6A-95
Kusuda, L., 358
Kuzel, T., 275

Lai, C., 6A-62
Lai, H., 504, 510
Lai, S., 504, 510
Lai, Y.-H., 108, 1117
Lakshmanan, Y., 1178
Lallas, C.D., 166
Lamm, S., 510
Landis, J.R., 6A-67
Lange, P.H., 402, 1126
Leak, B.J., 975
Lee, C.T., 168, 594
Lee, D., 530
Lee, F., 518
Lee, J.J., 4A-4, 4A-205
Lee, K.L., 4A-200
Lee, S.K., 363
Lee, T.T., 102
Lee, Y.-H., 872
Lee, Z.D., 611
Lefaucheur, J.-P., 306
Legrand, P., 617
Lehmann, J., 717
Leibovitch, I., 159, 946
Leinonen, S., 30
Lembo, A., 117
Lepor, H., 466, 491, 737, 742, 4A-202
Lerner, S.P., 60, 554
Leu, H.-S., 246
Leveillee, R.J., 866
Levin, H.S., 281
Lewis, J.H., 169
Lewis, R., 960
Leyh, H., 878
Liberman, J.N., 1044
Liberti, M., 1059
Lieberman, R., 4A-1, 4A-4, 4A-46, 4A-129, 4A-194, 4A-205, 4A-220, 4A-224
Liebert, M., 6A-7
Lief, J.H., 524
Lightfoot, M., 434
Lin, C.-S., 837
Lin, J.S.N., 365, 837
Lin, V.K., 170
Lin, Y.M., 365, 837
Linet, O.I., 536
Liotta, L.A., 4A-160
Lippman, S.M., 4A-4, 4A-205
Lipton, R.B., 1044
Littrup, P.J., 4A-121
Litwin, M.S., 499, 599, 604
Liu, I.J., 108, 1117
Liu, J.-H., 650
Liukkonen, T., 680
Lobel, B., 628
Loch, T., 717
Loening, S.A., 675
Loertzer, H., 900
Long, J.P., 518
Longcope, C., 930
Lopaczynski, W., 4A-194
Lopes, J.F., 1156
Losa, M.G., 71
Loughman, B.E., 4A-216
Love, K.D., 169
Lowe, F.C., 407, 877, 1072
Lu, J.D., 769
Lubeck, D.P., 6A-62
Lubet, R.A., 4A-46
Luciani, L., 206
Lukkarinen, O., 30, 680
Lumerman, J., 342
Lumey, L.H., 4A-202
Lümmen, G., 314
Lund, R.H., 1073
Lutgendorf, S.K., 422
Lynne, C.M., 670

Macairan, M.L., 999
Macaluso, J.N., Jr, 518
Machtens, S., 193
Macville, M.V.E., 266
Macy, M., 1117
Madersbacher, S., 389, 567
Madjar, S., 670
Maekawa, S., 721
Mahajan, R., 906
Mairinger, T., 4A-129
Majeed, N., 4A-86
Makuuchi, M., 975
Malkowicz, S.B., 286
Mallouh, C., 183
Malone, W.A., 4A-46
Manganelli, A., 117
Manley, S., 1128
Manola, J., 122
Manunta, A., 628
Manzoni, C., 154
Marberger, M., 66, 567
Marcovich, R., 806
Marks, L.S., 999, 4A-132, 4A-191
Marnett, L.J., 4A-137
Marrocco-Trischitta, M.M., 310
Marschke, P., 491
Marshall, J.R., 4A-185
Martin, J.K., Jr, 1025
Martin, S., 491, 742
Martin García, B., 685
Maruyama, T., 1151
Marvel, R., 6A-9
Mascarenhas, B., 168
Massad, C., 1178
Masumori, N., 270
Matin, S.F., 1166
Matsuta, Y., 701
Matteson, J.R., 783
Matthews, Y.L., 6A-67
Mayer, R., 434
Mayher, B.E., 439
Mazzucchelli, R., 117
McConnell, J.D., 170, 554
McCullough, T.C., 1078
McDougall, E.M., 447
McKenna, P.H., 1178
McKinlay, J.B., 930
McLeod, D., 217, 225, 399
McLeod, D.G., 481
McNeill, S.A., 459
Meehan, A., 1073
Melamed, J., 4A-202
Merikanto, J., 30
Merrick, G.S., 524
Mesrobian, H.-G.O., 341
Meyer, J., 866
Meyers, D., 6A-22
Meyers, M., 4A-77
Meyskens, F.L., Jr., 4A-4, 4A-171, 4A-178
Micksche, M., 567
Mihm, F., 365
Miki, T., 376
Miles, B.J., 8
Miller, K., 1006
Miller, M.C., 1105, 4A-164
Miró, R., 986
Miyake, H., 188
Mizutani, Y., 993
Mobley, D., 1073
Moghaddami, M., 573
Mohr, B.A., 930
Montie, J.E., 91, 133, 1128
Montironi, R., 117
Montoya, J., 1087

Mor, Y., 159, 946
Moran, E.M., 275
Mordhorst, J., 878
Moreno, R.A., 816
Morey, A.F., 788
Moriarty, R.P., 555
Moro, U., 78
Moskalik, A., 1128
Moslehi, J., 1178
Moudouni, S.M., 628
Moul, J.W., 4A-174
Mouly, P., 443
Movsas, B., 821
Muenchen, H.J., 366
Mulhall, J.P., 1160
Mulholland, G.S., 769
Müller, M., 1006
Mulvey, M.A., 6A-56
Mungan, U., 895
Munson, P.J., 4A-154
Munver, R., 166
Muraishi, O., 1038
Mutchnik, S., 365
Mutchnik, S.E., 239
Muto, G., 117
Myers, C., 4A-73
Myers, R.P., 491

Nadler, R.B., 275, 798, 1163
Nagler, H.M., 783
Nakai, O., 975
Nam, R., 471
Nam, R.K., 199
Nanni, L., 154
Nap, M., 747
Naqibuddin, M., 925
Narayan, P., 466, 1073
Nardi, P., 342
Narod, S.A., 199
Nath, R.K., 211
Nelson, P.S., 4A-154
Nelson, W.G., 4A-1, 4A-4, 4A-39, 4A-56, 4A-103
Netto, N.R., Jr, 816
Neubauer, B.L., 4A-64, 4A-68
Newman, R., 800
Ng, C.S., 911
Nguyen, A.T., 633
NIDDK/ICA Interstitial Cystitis and Bladder Research Abstracts, 6A-100
Nicar, M.R., 471
Nickel, J.C., 1082
Nicodemi, E.M., 310
Nieder, A.M., 737
Niederberger, C., 208
Nishizawa, O., 270
Nitti, V.W., 674
Noh, P.H., 351
Noriki, S., 257
Nouri, M., 168
Novick, A.C., 252, 365
Nutahara, K., 936
Nyberg, L.M., 6A-67, 6A-95

Obek, C., 510
Oberneder, R., 690
Oda, K., 721
O'Donnell, C., 481
O'Donnell, M.A., 621
O'Dowd, G.J., 1105
Ogawa, O., 993
Ogura, K., 721
Oh, W.K., 122
Okada, K., 257, 376
Okada, T., 721
Okada, Y., 975
Okamoto, M., 188
Okegawa, T., 936
Okihara, K., 376
Okubo, K., 701, 721
Optenberg, S., 733
Ornish, D.M., 4A-200
Ortenberg, J., 554
Otto, T., 55
Özen, H., 323
Özer, E., 895

Paananen, I., 30
Paccotti, P., 176
Padley, R.J., 4A-73, 4A-86
Pagano, F., 117
Pahlavan, S., 60
Päivänsalo, M., 30
Palcic, B., 4A-129
Pamukcu, R., 4A-73
Pantuck, A.J., 4A-95
Papadopoulos, I., 234
Park, J.M., 6A-30
Park, K., 1189
Park, R., 742
Park, Y.H., 371
Parker, R.G., 1121
Parsons, C.L., 428
Parsons, J.K., 428, 1013
Partin, A.W., 1, 481, 707, 1033, 1100, 1105, 4A-4, 4A-115, 4A-132, 4A-191
Patard, J.J., 617, 628, 883
Patel, R.V., 45
Pathak, H.R., 906
Paul, R., 878
Pautler, S.E., 230
Paweletz, C.P., 4A-160
Payton, T.R., 301
Pearle, M.S., 562, 866
Peche, W.J., 347
Peereboom, D.M., 281
Peltier, A., 712
Penson, D.F., 499
Pera, R.A.R., 530
Perälä, J., 30
Perez-Brayfield, M.R., 1178
Perkash, I., 127
Perrelli, L., 154
Perugia, G., 1059
Petricoin, E.F., III, 4A-160
Pettengill, E.B., 4A-200
Phillips, T.L., 102
Piantadosi, S., 707, 4A-205
Pickett, B., 102, 955
Pienta, K.J., 366
Pike, S.C., 554
Pintus, C., 154
Plante, P., 443
Planz, B., 66
Platz, E.A., 204
Politano, V.A., 670
Pollak, M., 4A-86
Poncza, P.J., 366
Ponsky, J.L., 21
Ponsky, L.E., 21
Pontonnier, F., 443
Porpiglia, F., 176
Potenzoni, D., 117
Potter, S.R., 1100
Powell, I.J., 4A-178
Prange, W., 486
Prat, E., 986
Prayer-Galletti, T., 117
Preminger, G.M., 166, 866
Prins, A., 763, 1093
Prins, H.J., 1133
PROSCAR Long-Term Efficacy and Safety Study Group, 1073
Pruchnic, R., 826
Pus, N., 230
Putzi, M.J., 4A-103
Pycha, A., 389

Qu, Z., 826

Rackley, R.R., 911
Radomski, S.B., 438
Raghow, S., 4A-68
Raitanen, M.-P., 680
Ramchandani, P., 660
Ramon, J., 159, 946
Ratliff, T., 422
Ratner, V., 6A-1, 6A-89
Rayford, W., 146
Rebollo Rodrigo, M.H., 685
Remzi, M., 66
Renard, F., 712
Reuter, V.E., 801, 1179
Rhodes, T., 1087
Ringhofer, H., 389
Rink, R.C., 338, 554
Riss, T.L., 4A-141
Rivera, V.M., 239
Roach, M., III, 102, 955
Roberts, W.W., 1033
Rodriguez, F., 71
Rodriguez, R., 112
Rodriguez Matas, M.J., 154
Roehrborn, C.G., 66, 459, 1087
Romanzi, L.J., 1145
Roobol-Bouts, M., 83
Roos, B., 510
Roos, B.A., 504
Rosenblum, N., 737
Roset, M., 71
Rossi, S., 78
Rothrock, N.E., 422
Rovner, E.S., 262, 660
Rübben, H., 55, 314
Rubin, J.M., 1128
Rubin, J.T., 168
Rubin, M.A., 394, 806, 832, 1128
Rukstalis, D.B., 34
Russack, V., 6A-67
Russo, P., 168, 633
Rutchik, S.D., 146
Ryan, A., 4A-230
Rybicki, L.A., 252
Ryu, S.B., 1189

Saad, A.G., 365
Saboorian, H.H., 562
Sadeghi-Nejad, H., 142
Sáenz de Tejada, I., 585
Sağol, O., 895
Saint, F., 617, 883
Sakr, W.A., 4A-4, 4A-115
Salomon, L., 617, 883
Saltzman, B., 1073
Samadi, A.A., 183
Sánchez-Ortiz, R.F., 262
Sant, G.R., 6A-1, 6A-2, 6A-47, 6A-62, 6A-82
Santinelli, A., 117
Santoni, J.-P., 459
Santos, P.B.C., 999
Sarkozy, A., 1059
Sartor, O., 399, 727
Sasaki, S., 1151
Scardino, P.J., 4A-28
Scardino, P.T., 211, 594, 1016
Schaeffer, A.J., 556
Schalow, E., 800
Schatzl, G., 567
Schechter, P.J., 301
Scheller, F., 193
Schellhammer, P., 217, 225
Schellhammer, P.F., 555, 727
Scherz, H.C., 1178
Schilling, J.D., 6A-56
Schlatmann, T.J.M., 1068
Schlegel, P.N., 334
Schlossberg, S.M., 555
Schmidt, S., 717
Schmitt, B., 727
Schnall, M.D., 660
Schneede, P., 690
Schneider, T., 314
Schnorr, D., 675
Schoenberg, M., 849
Schoenberg, M.P., 266
Schoenberg, M.S., 1013
Schonfeld, W.H., 499
Schoor, R.A., 556, 1163
Schottenfeld, D., 91
Schover, L.R., 252
Schrader, M., 1006
Schreiber, A., 4A-95
Schröder, F.H., 83
Schubert, J., 207
Schulam, P.G., 554
Schuster, T.G., 639
Sciobica, F., 1059
Scott, C.A., 78
Sebe, P., 168
Sech, S., 1087
Sedelaar, J.P.M., 914
Segall, G.M., 108
Seguin, P., 443
Seifman, B.D., 133, 832
Seitz, C., 66
Selli, C., 78, 117

Selvaggi, F.P., 117
Senger, D.R., 4A-143
Seo, J.J., 1189
Seo, J.T., 921
Seo, S.I., 371
Sfakianaki, E., 1167
Sfakianakis, G.N., 1167
Shabsigh, R., 1141
Shalev, M., 8
Shariat, S.F., 60
Sharifi, R., 275
Sharma, A., 142
Sharp, L.K., 275
Shelton, J., 976
Shetty, S.D., 169
Shi, R., 471
Shimada, T., 579
Shimizu, H., 579
Shinohara, K., 518
Shioji, Y., 1038
Shoenfelt, J., 6A-9
Shokeir, A.A., 1055
Shu, H.-K.G., 102
Shuler, C.L., 599, 604
Siegel, R.L., 960
Sigman, C.C., 4A-46
Silver, R.I., 790, 795
Simon, M.A., 554
Singer, A.J., 363, 554
Siroky, M.B., 800
Sis, B., 895
Siu, W., 800
Sklar, G.N., 138
Slaton, J.W., 852
Slaughenhoupt, B.L., 209
Slawin, K., 211
Slezak, J.M., 1033
Slichenmyer, W., 4A-77
Sloan, J.A., 4A-205, 4A-235
Smallridge, R.C., 1025
Smeets, D.F.C.M., 266
Smith, A.D., 356
Smith, D.P., 778
Smith, D.S., 97
Smith, E., 1178
Smith, L.E.H., 4A-143
Smith, R.B., 1121
Smith, S.L., 1025
Snodgrass, W.T., 781
Snyder, H.M., III, 351
Sokoll, L.J., 707
Soloway, M., 949
Soulié, M., 443
Sousa-Escandón, A., 49
Sözen, S., 323
Sperling, H., 314
Spermon, J.R., 747
Srinivas, M., 547
Srinivas, S., 127
Stapleton, A.M.F., 573
Stecher, V.J., 960
Steele, V.E., 4A-46
Steinberg, G.D., 355, 1063
Steinberg, H., 554
Steiner, M.S., 382, 491, 4A-68
Stepp, H., 690, 690
Stewart, W.F., 1044
Stief, C.G., 193
Stillo, F., 310
Stock, J.A., 783
Stöckle, M., 717
Straub, B., 1006
Strawderman, M.S., 91
Streem, S.B., 21
Stricker, B.H.C., 970
Study Group, 866
Sturkenboom, M.J.C.M., 970
Su, L.-M., 360
Sugaya, Y., 1038
Sugiyama, M., 975
Suhr, J., 55
Sullivan, G., 146
Suzuki, K., 1038
Suzuki, S., 579
Suzuki, Y., 257
Swanson, M.G., 4A-124
Sweat, G., 217, 225
Sweet, J., 199
Syllwasschy, J., 314

Tacker, J.R., 26
Takahashi, S., 811
Takamatsu, T., 376
Takenaka, I., 981
Tammela, T.L.J., 680
Tan, J.K., 230
Tanaka, Y., 270, 811, 975
Taneja, S., 4A-202
Tash, J.A., 334
Taylor, A., 91
Taylor, J.M.G., 91
Tazaki, H., 183
Tefekli, A., 328, 758
Teichman, J.M.H., 432, 866
Teixeira, C.E., 816
Tekgül, S., 323, 542
Tekin, A., 542
Tellaloğlu, S., 328
Terachi, T., 993
Terada, N., 701
Terris, M.K., 26, 108, 127, 800, 943, 1117
Terzolo, M., 176
Theoharides, T.C., 6A-47
Thomas, A.C., 338
Thomas, S., 763, 1093
Thompson, I., 217, 225
Thompson, I.M., 4A-230
Thompson, I.M., Jr, 733, 788
Thompson, T.C., 8
Thoulouzan, M., 443
Tiguert, R., 949
Tindall, D.J., 4A-28
Tinzl, M., 1100
Toi, A., 199
Tokue, A., 1038
Tolcher, A.W., 4A-86
Tolterodine Study Group, 414
Tomaszewski, J.E., 6A-67
Tondravi, M., 611
Tongco, W.P., 495
Torre, P., 4A-202
Tortorelis, D.G., 183
Trachtenberg, J., 199, 471
Traxer, O., 168, 562
Tricoli, J.V., 821
Trock, B.J., 4A-241
True, L.D., 611
Trump, D.L., 4A-64
Truss, M.C., 193
Tsai, M.-F., 246
Tsai, Y.-S., 837
Tsui, K.-H., 246
Tsukamoto, T., 270
Tsukayama, C., 721
Tu, L.M., 536
Tuna, B., 895
Turek, P.J., 530
Tyler, V.E., 999
Tzen, K.-Y., 246
Tzortzis, V., 966

Uckert, S., 193
Ukimura, O., 376
Unda, M., 71
Urban, D.A., 4A-220
Usta, M.F., 758
Uzzo, R.G., 252

Vaidya, A., 949
Valicenti, R.K., 769
van Andel, G., 1068
van der Horst, H.J.R., 1068
van der Kwast, T., 83
van der Lei, J., 970
van Haarst, E.P., 1068
Van Kerrebroeck, P., 414
van Leenders, G.L.J.H., 914
Van Nieuwenhuize, A., 975
van Roermund, J.G.H., 914
van Velthoven, R., 712
van Venrooij, G.E.P.M., 695
Varricchio, C., 4A-235
Vazzoler, N., 443
Veltri, R.W., 1105, 4A-164
Verhage, B.A.J., 97
Vesprini, D., 199
Vessella, R.L., 611
Vigneault, E., 102
Vigneron, D.B., 4A-124
Viitanen, J., 680
Vira, M., 554
Vis, A.N., 83
Vo, Q., 6A-26
Vohra, A.K., 169
Vutuc, C., 567

Wade, M., 146
Wadhwa, S.N., 644
Waggle, D.H., 4A-77
Walczak, J., 4A-81
Walden, P., 4A-202
Waldert, M., 66
Waldstreicher, J., 1073
Waldstreicher, J.A., 4A-64
Walsh, P.C., 491, 707, 1020, 1033, 1112
Wang, J.-S., 872
Wang, L.-P., 6A-67
Wang, W.-S., 650
Wang, Z.-Y., 6A-40
Warolin, K.L., 499
Warren, J.W., 6A-9, 6A-22
Wasson, J., 217, 225
Watanabe, Y., 721
Watumull, L., 554
Wechter, W., 4A-73
Wehner, M.S., 495
Wei, J.T., 91
Weichert-Jacobsen, K., 234, 717
Wein, A., 414, 1044, 6A-1
Wein, A.J., 245, 262, 286, 660
Weinberg, V., 955
Weiner, S., 1073
Weiss, H.L., 4A-220
Wells, G., 1073
Wesselmann, U., 6A-32
Westra, W., 1066
Wheeler, T.M., 60
Whitmore, K., 6A-9, 6A-62
Whittington, R., 286
Wijkstra, H., 914
Wilding, G., 4A-4, 4A-56, 4A-81
Williams, A.L., 806, 832
Williams, E.D., 4A-100
Williams, T., 6A-67
Williams, T., Jr., 4A-81
Wilson, D., 4A-95
Wilson, S.K., 142
Wilt, T.J., 727
Winfield, H.N., 365
Wissel, P.S., 4A-64
Witjes, J.A., 266, 747
Wojno, K., 1128
Wojno, K.J., 91
Wolf, J.S., Jr, 133, 599, 604, 639, 806, 832
Wood, H., 4A-81
Wood, P.J., 4A-124
Wren, S.M., 800, 943
Wu, C.L., 925
Wu, M.H., 365
Wu, X.-X., 993
Wyndaele, J.J., 655

Xia, P., 102
Xu, J., 6A-22

Yaman, O., 1184
Yang, M.-H., 650
Yang, X.J., 296, 1063
Yannakoyorgos, K., 966
Yashi, M., 1038
Yen, C.-C., 650
Yeşilli, C., 1184
Yılmaz, E., 623
Yiou, R., 306
Yip, S.K.H., 206
Yohannes, P., 356
Yokoi, S., 17
Yokoyama, K., 376
Yokoyama, T., 826
Yörükoğlu, K., 895
Yoshimura, K., 701
Yoshimura, N., 826
Yu, C.-C., 872
Yu, H., 471
Yücel, B., 758
Yun, T.J., 611

Zaak, D., 690
Zaatari, G.S., 365
Zafar, M.B., 108
Zahurak, M.L., 707
Zammattio, S., 883
Zattoni, F., 117
Zeleniuch-Jacquotte, A., 4A-202
Zermann, D.-H., 207
Zhang, C.-O., 6A-9
Zhang, X., 981
Zhao, X., 860
Zhou, Z., 1044
Zietman, A., 217, 225
Zimmerman, B., 422
Zinner, N., 414
Zisman, A., 4A-95
Zuccalà, A., 1059
Zupkas, P., 428

SUBJECT INDEX

Page numbers for the Supplement to the April issue are preceded by a "4A-"; page numbers for the Supplement to the June issue are preceded by a "6A-."

Abdominal leak point pressures, 40
Abdominoperineal resection, prostate cancer screening prior to, 943
Acapodene, 4A-68
Acid phosphatase, prostate cancer recurrence predicted using, 707
Adrenocortical tumors, 176
African-Americans
  prostate cancer incidence, 4A-178
  prostate-specific antigen reference values, 91
Alfuzosin, 459
Alpha-blockers
  myosin heavy chain gene expression downregulation by, 170
  thermotherapy vs., for benign prostatic hyperplasia symptoms, 66
Alprostadil, 536
American Urological Association Best Practice Policy, 217, 225, 599, 604
American Urological Association Symptom Score
  quality of life evaluations, 112
  sociodemographic variables that affect, 71
5-Aminolevulinic acid fluorescence endoscopy, 690, 1059
Anastomotic strictures, after radical prostatectomy, 742
Anatrophic nephrolithotomy, 161
Androgen blockade
  nonsteroidal antiandrogens and, for prostate cancer, 727
  prostate cancer prevention benefits of, 4A-64
  radical surgery after, 117
Androgen deprivation therapy, bone mineral density effects of, 127
Androstanediol glucuronide, 930
Angiogenesis
  chemopreventive trial biomarker use, 4A-143
  prostate cancer, 376
  transitional cell carcinoma, 895, 981
Angiomyolipomas, 554
Angiotensin-converting enzyme inhibitors, 193
Angiotensin II, penile erection regulated by, 193
Anti-Fas monoclonal antibody, effect on doxorubicin treatment of renal cell carcinoma, 993
Antioxidants, 4A-90
Anti-prostate-specific membrane antigen monoclonal antibodies, 1179
Apoptosis
  chemopreventive trial biomarker use, 4A-141
  gene therapy for inducing, 8
  nonsteroidal anti-inflammatory drugs that promote, 4A-73
  protein kinase C in, 860
  retinoblastinoma gene activation and repression of c-*myc* precede, 860
  in transitional cell carcinoma, 981
Artificial urinary sphincter, nocturnal deactivation of, 1051
Arzoxifene, 4A-68
Azoospermia
  epididymal obstruction as cause of, 1138
  testicular sperm extraction, 334
  varicocele repair, 328

Bacille Calmette-Guérin
  bacteriostatic urethral lubricant effects, 900
  bladder cancer treated using, 883
  tolerance and efficacy of
    leukocyturia as predictor of, 617
    studies, 883
Bacteria, *Staphylococcus saprophyticus*, 17
Benign prostatic hyperplasia
  bladder tumor vs., 1166
  17 hydroxylase gene polymorphisms, 567
  lower urinary tract symptoms
    American Urological Association Symptom Score for assessing, 71
    bladder capacity and, 1093
    International Prostate Symptom Score, 695
    postvoid residual urine, 459
    quality-of-life assessments, 695
    thermotherapy vs. alpha-blockers for, 66
  smooth muscle expression in, 170
  transition zone index, 524
  treatment of
    alpha-blockers, 66
    finasteride. *See* Finasteride
    tamsulosin, 466
    transurethral microwave thermotherapy, 66, 701
    vitamin D receptor polymorphisms and, 567
Biliary calculi, 21
Biofeedback, for daytime syndrome of urinary frequency, 791
Biopsy, prostate
  chemopreventive agents evaluated using, 4A-191
  digital rectal examination indications for, 1100
  posterolateral, 1112
  transition zone, 1117
  transrectal, local anesthetic effects on patient recovery after, 925
  transrectal Doppler ultrasound and, 1128
Bladder
  carcinoma in situ of, 60
  dysfunction of, muscle-derived cell transplantation for, 826
  endometriosis, 798
  exstrophy, 774, 906
  filling, electrical thresholds for quantifying perception of, 655
  functional capacity of, lower urinary tract symptoms and, 1093
  overactive, 414, 1044
  pheochromocytoma, laparoscopic management of, 365
Bladder cancer. *See also* Transitional cell carcinoma; Urothelial cell carcinoma
  bacille Calmette-Guérin maintenance therapy, 617, 883
  benign prostatic hyperplasia vs., 1166
  biomarkers for diagnosing, 847, 849
  biopsy and radical cystectomy findings, 1063
  BTA *stat* test, 680, 685
  chromosomal imbalances associated with, 986
  gene therapy for, 579
  matrix metalloproteinases excretion in urine, 675
  metastases, surgical resection of, 55
  p53 gene mutations in, 852
  refractory, 55
Bladder neck
  reconstruction of, urinary continence after, 774
  suspension of, 45
Bladder outlet obstruction, bladder function evaluations using detrusor and urinary growth factors, 371
Bone mineral density, androgen deprivation therapy effects on, 127

© 2001, Elsevier Science Inc.
ALL RIGHTS RESERVED

0090-4295/01/$20.00
PII S0090-4295(01)01200-6

Book Reviews
Atlas of Congenital Anomalies of the External Genitalia, 209
Men's Health, 209
Textbook of Prostatitis, 396
The 5-Minute Urology Consult, 396
WHO Manual for the Standardized Investigation, Diagnosis and Management of the Infertile Male, 208
Bradykinin, penile erection regulated by, 193
BTA *stat* test, for bladder cancer diagnosis, 680, 685
Buschke-Löwenstein tumors of penis, 966

Calcium hydroxylapatite, 434
Cancer Research Foundation of America, 4A-52
Carcinoma in situ, E-cadherin expression in, 60
Cavermap Surgical Aid, 491
Cavernous nerves, 491
Cecil-Culp technique, 347
Cells
apoptosis of. *See* Apoptosis
oxidative stress effects, 4A-137
proliferation of, in transitional cell carcinoma, 981
signal transduction modulator effects, 4A-77
tyrosine kinase inhibitor effects, 4A-77
Chemoprevention
agents
androgen antagonists, 4A-64
antioxidants, 4A-90
antiproliferative or differentiating agents, 4A-81
biomarkers for evaluating, 4A-100, 4A-132
description of, 4A-46
development of, 4A-56
FDA approval of, 4A-213
molecular approaches for identifying, 4A-100
nonsteroidal anti-inflammatory drugs, 4A-73, 4A-81
novel types of, 4A-86
prostate needle biopsy for evaluating, 4A-191
selective estrogen receptor modulators, 4A-68
signal transduction modulators, 4A-77
target populations for testing, 4A-171
tyrosine kinase inhibitors, 4A-77
biomarkers
agent evaluations using, 4A-100, 4A-132
angiogenesis as, 4A-143
apoptosis as, 4A-141
description of, 4A-46
intermediate endpoint, 4A-164
surrogate endpoint, 4A-241
endpoints for evaluating efficacy of intervention
analytical validation of, 4A-164
computer-assisted image analysis-derived, 4A-129
magnetic resonance spectroscopic imaging metabolic information, 4A-124
quality control of, 4A-164
quality of life, 4A-235
standardization of, 4A-164
surrogate endpoint biomarkers, 4A-241
high-grade prostatic intraepithelial neoplasia, 4A-115
National Cancer Institute Workshop summary, 4A-4
prostate-specific antigen uses, 4A-132, 4A-174
transrectal ultrasonography, 4A-121
trials
in African-Americans with hereditary/familial history of prostate cancer, 4A-178
angiogenesis as biomarker in, 4A-143
apoptosis as biomarker in, 4A-141
Bayesian monitoring of, 4A-220
clinical models, 4A-171
designing of, 4A-205 4A-216, 4A-224
drug approval endpoints, 4A-213
flutamide, 4A-188
oxidative stress in, 4A-137
patient selection methods, 4A-124
phase 2, 4A-220
phase 3, 4A-224
populations for, 4A-171, 4A-216
preprostatectomy setting, 4A-194
Prostate Cancer Prevention Trial, 4A-230
prostate-specific antigen-enhanced testing, 4A-174
prostate-specific antigen failure, 4A-202
quality of life endpoints, 4A-235
selenium supplementation, 4A-182, 4A-185
soy protein, 4A-202
stromal-epithelial interactions, 4A-194
surrogate endpoint biomarkers, 4A-241
Chemotherapy. *See also specific agent*
prostatic tuberculosis treated using, 872
renal cell carcinoma, 650
testicular cancer
description of, 555
residual masses surgically resected, 323
Cisplatin, ionomycin and, 188
Computed tomography
psoas abscess evaluations, 246
unenhanced helical, for renal colic evaluations, 342
Continence
anastomotic stricture effects, 742
bladder neck reconstruction effects, 774
female, neuroanatomy of, 382
urethral-sparing prostatectomy effects on, 495
Corpus cavernosa
hypercholesterolemia effects, in experimental model, 1184
phenolamine and L-arginine for neurogenic relaxation of, 585
scorpion venom for relaxation of, 816
traumatic rupture of, 319
Cranberry juice and concentrate tablets
nephrolithiasis risks, 26
oxalate levels, 26
urinary tract infections treated using, 26, 407
Cryoablation, 34
Cryosurgery, prostate cancer treated using, 518
Cystectomy
biopsy findings and, for assessing grade and depth of invasion of bladder cancer, 1063
for bladder exstrophy, 906
Cystitis, interstitial. *See* Interstitial cystitis
Cystoceles, abdominal leak point pressure effects, 40
Cystoscopy
5-aminolevulinic acid fluorescence endoscopy vs., 690, 1059
hematuria, 604
radical prostatectomy and, 946
vesicoureteral reflux repair and, 1156

Daytime syndrome of urinary frequency, 791
Detrusors, 371
Diet, 4A-31, 4A-200
Digital rectal examination
prostate biopsy indications and, 1100
prostate volume assessments by, transrectal ultrasonography for determining accuracy of, 1087
Distigmine bromide, 270
Diverticula, urethral, 660
Docetaxel, prostate cancer cell lines apoptosis induced by, 366
Doxorubicin, anti-Fas monoclonal antibody effects on, 993

E-cadherin, 60
Ejaculatory dysfunction, in elderly patients, 763
Elderly patients
  ejaculatory dysfunction, 763
  finasteride efficacy and safety for, 1073
Endometriosis, bladder, 798
Endoscopy
  5-aminolevulinic acid fluorescence, for transitional cell carcinoma detection, 690
  Jackson-Pratt drain retrieved using, 973
  laser papillectomy, 832
  urethral injuries treated using, 439, 628
Epididymal obstruction, 1138
Epoetin alfa, 737
Erectile dysfunction
  Doppler ultrasound evaluations, 623
  in elderly patients, 763
  family practitioner diagnosis of, 146
  neurogenic, 306
  penile prosthesis for. *See* Penis, prosthesis
  psychogenic vs. organic causes of, 758
  radiation therapy-induced, 102, 769, 955
  treatment of
    alpha-adrenergic receptor antagonists and L-arginine or sildenafil, 585
    alprostadil, 536
    angiotensin-converting enzyme inhibitors, 193
    Erectile Dysfunction Inventory of Treatment Satisfaction, 960
    sildenafil. *See* Sildenafil
    Topiglan, 301
Erection
  alprostadil for, 536
  angiotensin II, 193
  bradykinin's role in, 193
  Topiglan for, 301
Estramustine, 281
Etoposide, 281
Exstrophy of bladder
  cloacal, 1178
  cystectomy for, 906
  urinary continence determinants in, 774
Extracorporeal shock wave lithotripsy, fishnet gantry for, 795
Extravesical seromuscular tunnel ureteroneocystostomy, 1055

Fibrin glue, for wound closure in urinary tract, 806
Finasteride
  chemopreventive uses of, 4A-64
  efficacy and safety of, 1073
  saw palmetto vs., 999
Fistulae
  hypospadia, 351
  urethrocutaneous, 347
  vesicovaginal, 670
18-Fluoro-2-deoxyglucose positron emission tomography, 108
5-Fluorouracil with vinblastine and tamoxifen, for renal cell carcinoma, 650

Gallium-67 scans, psoas abscess evaluations, 246
Gene therapy
  prostate cancer prevention and treatment, 8, 4A-95
  transitional cell carcinoma treated using, 579
  vectors for, 8
Genitourinary melanoma, 633
Germ cell tumors, surgical resection of, 323
Glansectomy, for Buschke-Löwenstein tumors of penis, 966
Glans penis, sclerotherapy for malformations of, 310
Glanulopexy, 1160
Gleason system, 291
Glyoxalase I, 183
Gonadectomy, laparoscopic, 554

Hematuria
  American Urological Association Best Practice Policy, 599, 604
  characteristics of, 599
  definition of, 599
  diagnostic algorithm, 889
  interstitial cystitis, 262
  patient evaluation, 604
  prevalence of, 599
Hemorrhagic cystitis, 168
Herbal remedies
  PC-SPES, 122
  saw palmetto vs. finasteride, 999
High-grade prostatic intraepithelial neoplasia
  chemoprevention trials in individuals with, 4A-185
  description of, 296
  flutamide trials, 4A-188
  prostate cancer predictions, 486, 4A-115, 4A-185
Hinman, Frank Jr., 843
Holmium laser
  prostatic stent removed using, 166
  transurethral resection of the prostate gland vs., 454
Horseshoe kidney, renal masses in, 168
Hydronephrosis, antenatal, 1178
Hypertension, 363
Hypospadias
  epidemiology of, 788
  incidence of, 151, 788
  prostatic utricle associated with, 1151
  repair of
    spongiosum preservation for reducing fistula incidence, 351
    tubularized incised plate for, 778
  studies of, 151
Hypoxia, vascular endothelial growth factor expression effects caused by, 821

Ileal loop diversion, parastomal hernia after, 551
Immunotherapy, 168
Impotence. *See* Erectile dysfunction
Incontinence
  sling surgery, 45, 49
  stress. *See* Stress incontinence
  treatment of, patterns in, 45
Indium-111 capromab pendetide (ProstaScint), 399, 402
Insulin-like growth factor, 471
Insulin-like growth factor binding protein-2, 471
Insulin-like growth factor binding protein-3, 471
Intensity-modulated radiation therapy, 102
International Prostate Symptom Score, 695
Interstitial cystitis
  antiproliferative factor as urine marker for, 6A-9
  biopsy features, 6A-67
  in children, 6A-30
  chronic visceral pain syndrome, 6A-32
  clinical presentation of, 6A-26
  controversies associated with, 6A-67, 6A-82
  diagnosis of, 6A-26, 6A-82
  epidemiology of, 6A-95
  epidermal growth factor as urine marker for, 6A-9
  genetic approaches, 6A-7
  hematuria, 262

heparin-binding epidermal growth factor-like growth factor as urine marker for, 6A-9
mast cell involvement in, 6A-47
in monozygotic and dizygotic twin pairs, 6A-22
National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association and Scientific Conference on Interstitial Cystitis, 6A-2
NIDDK/ICA Interstitial Cystitis and Bladder Research abstracts, 6A-100
O'Leary-Sant Interstitial Cystitis Symptom Index, 6A-62
pentosan polysulfate sodium trial, 6A-62
percutaneous sacral third nerve root evaluation (letter), 207
potassium sensitivity, 428
research, 6A-7
stress-related exacerbation of, 422
treatment of, 6A-26
urine biomarkers for, 6A-9, 6A-15
Interstitial Cystitis Data Base Study, 6A-67
Intrinsic sphincteric deficiency, 382
Ionomycin, renal cell carcinoma treated using, 188

Jackson-Pratt drain, endoscopic retrieval of, 973

Ki-67, 176
Kidneys
radiofrequency ablation of, laparoscopically and percutaneously delivered, 976
retroperitoneoscopic nephrectomy and nephroureterectomy evaluations, 644

Laparoscopic surgery. *See specific procedure*
Leukocyturia, bacille Calmette-Guérin therapy tolerance and efficacy predicted by, 617

Magnetic resonance imaging
blood oxygenation level-dependent-based functional (BOLD-fMRI), for evaluating cerebral regions of female sexual arousal response, 1189
dynamic endorectal, 721
neurovascular bundle involvement assessments, 721
spectroscopic imaging and, for patient selection for prostate cancer chemoprevention trials, 4A-124
urethral diverticula evaluations using, 660
Malacoplakia, 169
Malpractice litigation, 783
Matrix metalloproteinases, urinary excretion of, 675
Melanoma, genitourinary, 633
Microlithiasis, testicular, 1133
Monoclonal antibody
anti-Fas, effect on doxorubicin treatment of renal cell carcinoma, 993
anti-prostate-specific membrane antigen, 1179
Muscle-derived cell transplantation, in urinary tract smooth muscle, 826
Myosin heavy chain gene, alpha-blockers effects, 170

National Cancer Institute Workshop, 4A-4, 4A-86
National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association and Scientific Conference on Interstitial Cystitis, 6A-2
Nephrectomy
adrenalectomy and, simultaneous performance of, 878
partial
laparoscopic, cable-tie compression for, 562
urine leaks after, urethral stent placement for, 355
quality of life effects, 252
radical, en bloc with right hepatic lateral sector, 975
retroperitoneoscopic, for benign nonfunctioning kidneys, 644
transperitoneal laparoscopic, rapid ligation of renal hilum during, 360
Nephrolithiasis
cranberry concentrate tablets and risk of, 26
primary hyperparathyroidism as cause of, 554
Nephrolithotomy, anatrophic, 161
Nephrostomy, percutaneous, 547
Nephroureterectomy
laparoscopic
open surgical vs., 133
transitional cell carcinoma treated using, 448
retroperitoneoscopic, for benign nonfunctioning kidneys, 644
Neurogenic bladder, decompression sickness and, 365
Neuroinflammation, 6A-40
Neurovascular bundle
in prostate cancer, 721, 949
radical prostatectomy excision of, 1020
NIDDK/ICA Interstitial Cystitis and Bladder Research abstracts, 6A-100
Nonsteroidal antiandrogens, androgen blockade and, 727
Nonsteroidal anti-inflammatory drugs, 4A-73, 4A-81
Nuclear area index, 257

2-Octyl cyanoacrylate adhesive, 806
O'Leary-Sant Interstitial Cystitis Symptom Index, 6A-62
Orchiopexy, testicular sperm extraction after, 365
Osteoprotegerin, prostate cancer expression of, 611
Overactive bladder, 414, 1044
Oxalate, cranberry concentrate tablet levels of, 26

p53, in bladder cancer, 852
Pancreticobiliary calculi, 21
Papillectomy, endoscopic laser, 832
Parastomal hernia, synthetic mesh for repair of, 551
PC-SPES, 122
Pediatric patients
cloacal exstrophy, 1178
daytime syndrome of urinary frequency, 791
extracorporeal shock wave lithotripsy in, 795
hydronephrosis, 1178
hypospadias, 778
interstitial cystitis in, 6A-30
posterior urethral valves, 1178
prostatic abscess, 554
renal scintigraphy in, 1167
ureterocele, 554, 1178
ureteropelvic junction obstruction, 338, 542, 547
urethrocutaneous fistulae, 347
varicoceles in, 154
Pelvic fracture, urethral injury management effects on, 439
Penis
Buschke-Löwenstein tumors of, 966
corpus cavernosa of. *See* Corpus cavernosa
Doppler ultrasound of, 623
melanoma of, 633
prosthesis
in pelvic organ transplant patients, 138
reservoir herniation complications, 142
supersonic transporter deformity reconstructed using glanulopexy, 1160
radiation dose delivered to bulb of, impotence risks secondary to, 955
size of, effect on condom use, 314
spongiosum preservation for reducing fistula incidence after hypospadias repair, 351
thermal sensory testing of, 306

vascular abnormalities of, 758
Pentosan polysulfate sodium, 6A-62
Peyronie's disease, 753
Phenylbutyrate, 4A-81
Pheochromocytoma, 365, 1025
Platelet-derived endothelial cell growth factor, localization of, 376
Polyamine inhibitors, 4A-81
Positron emission tomography, 18-fluoro-2-deoxyglucose, 108
Potassium sensitivity test, 428
Priapism
description of, 169
high-flow, 800
incidence of, 970
in scorpion envenomation cases, 816
Prostate cancer
in African-American men, 4A-178
androgen-independent, 122
autosomal dominant inheritance of, 97
biomarkers
description of, 4A-103
prostate-specific antigen. *See* Prostate-specific antigen
proteomic-based approaches for identifying, 4A-160
sequence databases and microarrays for identifying, 4A-154
breast cancer and, similarities between, 4A-31
carcinogenesis processes, 4A-103
cell apoptosis
docetaxel-induced, 366
retinoblastinoma gene activation and repression of c-*myc* preceding, 860
chemoprevention of. *See* Chemoprevention
diagnosis and detection of
prostate-specific antigen. *See* Prostate-specific antigen
SRD5A2 polymorphic variants, 199
three-dimensional Doppler ultrasound, 1128
dietary influences, 4A-31, 4A-200
epithelial cell carcinogenesis, 4A-103
familial, 4A-178, 4A-182
18-fluoro-2-deoxyglucose positron emission tomography evaluations of, 108
gene therapy for, 8
Gleason system for grading, 291
glyoxalase I phenotype, 183
lymph node spread in, 481
metastatic, anti-prostate-specific membrane antigen monoclonal antibodies in, 1179
molecular pathogenesis of, 4A-39
neurovascular bundle, 721, 949
osteoprotegerin expression, 611
oxidative stress and, 4A-90, 4A-137
patient education, 230
prevention of
biological approaches, 4A-95
Cancer Research Foundation of America efforts, 4A-52
chemoprevention. *See* Chemoprevention
diet, 4A-200
gene therapy, 4A-95
selenium supplementation, 4A-182, 4A-185
strategies for, 4A-39
telomerase activity modulation, 4A-148
quality of life, 275
RANK ligand expression, 611
rectal tumors and, synchronous presentation of, 800
recurrence of
growth factors and, 471
high-risk patients for, 1033
predictors of, 476, 707
prostate-specific antigen for predicting, 476
serum acid phosphatase levels, 707
research, 4A-28
risk determinants and stratification
androstanediol glucuronide, 930
description of, 286
high-grade prostatic intraepithelial neoplasia findings, 486, 4A-115
serum hormones, 930
risk factors
description of, 183
diet, 4A-31
screening of. *See also* Prostate-specific antigen
in abdominoperineal resection patients, 943
description of, 83, 712
18-fluoro-2-deoxyglucose positron emission tomography, 108
staging of
artificial neural network model for, 481
indium-111 capromab pendetide scan, 402
magnetic resonance imaging, 721, 4A-124
three-dimensional grayscale ultrasound, 914
transition zone index of, 524
treatment of
androgen blockade with nonsteroidal antiandrogens, 727
androgen deprivation therapy, 127
comparisons among, 1121
costs, 499
cryosurgery, 518
PC-SPES, 122
radiation therapy, 769, 800, 955, 1121
sexual dysfunction secondary to, 769, 955
tumor angiogenesis in, 376
vascular endothelial growth factor expression in, hypoxia effects on, 821
Prostate Cancer Prevention Trial, 4A-230
Prostatectomy, radical
anastomotic strictures after, 742
androgen blockade before, 117
cystoscopy before, 946
epoetin alfa preoperatively administered, 737
estramustine and etoposide neoadjuvant therapy before, 281
margins after, 949, 1006
neurovascular bundle excision, 1020
prostate sampling for outcome predictions (letter), 394
recombinant erythropoietin, 737
recurrence of prostate cancer after
chemoprevention trials in patients at high risk for, 4A-202
high-risk patients for, 1033
predictors of, 476, 707
prostate-specific antigen velocity preoperative levels and, 476
serum acid phosphatase levels, 707
sural nerve grafting
description of, 211
harvesting techniques, 921
necessity evaluations, 1020
rationale for, 1016
survival after, geographic effects on, 504
T staging intraoperatively for nerve-sparing surgery decisions, 949
urethral-sparing, 495
Prostate gland
abscess, 554
biopsy of. *See* Biopsy
brachytherapy, 524
lymphatic drainage of, 389

tissue
CD40 expression, 573
saw palmetto effects, 999
thermal ablation of, 78
tuberculosis of, 872
volume assessments by digital rectal examination, 1087
Prostate-specific antigen
in African-American men, 91, 4A-174
American Urological Association Best Practice Policy, 217, 225
androgen suppression effects, 975
biochemical recurrence after radical prostatectomy predicted using, 476, 1006
cancer detection using
complexed forms, 1105
levels, 83, 217, 591
policies, 217
post-treatment follow-up, 225
ratios for, 936, 1105
staging, 225
studies of, 83, 712, 733, 936
transurethral resection of the prostate gland comparisons, 733
chemopreventive uses of, 4A-132, 4A-174
complexed/total, 936, 1105
in female urine, 717
free/total, 936, 1105
metastatic prostate cancer neovasculature expression of, 801
percent free, 594, 1105
race-specific reference values, 91
reverse transcriptase-polymerase chain reaction detection of, in surgical margins after radical prostatectomy, 1006
Prostatic intraepithelial neoplasia. *See* High-grade prostatic intraepithelial neoplasia
Prostheses, penile. *See* Penis, prosthesis
Proteomics, 4A-160
Prune-belly syndrome, 975, 1178
Psoas abscess, 246
Pubovaginal slings
release of, 358
suburethral placement of, 49
urethral erosion caused by, 159
Pyeloplasty, retroperitoneal laparoscopic vs. open, 443

Quality of life
American Urological Association Symptom Score evaluations of, 112
chemoprevention trial endpoint, 4A-235
overactive bladder effects, 1044
prostate cancer, 275
spousal assessments and ratings, 275
surgical procedure effects, 252
urinary tract symptoms suggestive of benign prostatic hyperplasia, 695

Radiation therapy
geographic and demographic variations in, 510
intensity-modulated, 102
prostate cancer and rectal tumors synchronously presenting, 800
sexual dysfunction induced by, 769, 955
testicular cancer treated using, 555
three-dimensional conformal, 102, 769, 955
ureteral stenosis secondary to, 1038
Radiofrequency ablation, of kidneys, 976
RANK ligand, 611
Raz Anchoring System (RAS), 666

5α-Reductase inhibitors, 4A-64
Renal calculi, ureterojunction obstruction and, 542
Renal cell carcinoma
incidental (letter), 206
liver invasion by, 975
metastatic
adrenal, 878
prostate-specific antigen expression by neovasculature, 801
recurrent, 168
treatment of
chemotherapy, 650
doxorubicin, anti-Fas monoclonal antibody effects on, 993
ionomycin, 188
nephrectomy, 252
tamoxifen, vinblastine, and 5-fluorouracil, 650
WHO grading system, 257
Renal colic, unenhanced helical computed tomography evaluations of, 342
Renal cysts
kidney function losses after, 363
sclerotherapy for, 30
Renal hemangioma, 975
Renal hilum, rapid ligation during transperitoneal laparoscopic nephrectomy, 360
Renal masses
in horseshoe kidney, 168
incidental, early intervention considerations for, 1013
open cryoablation of, 34
Renal oncocytoma, 365
Renal scintigraphy, 1167
Residents, personal finances management, 866
Retrograde urethrography, 1151
Retroviruses, 8

Saw palmetto, finasteride vs., 999
Sclerotherapy
99% ethanol, 30
glans penis malformations treated using, 310
renal cysts treated using, 30
Scrotal calcinosis, 365
Selective estrogen receptor modulators, 4A-68
Selenium supplementation, 4A-182, 4A-185
Seminomas
primary retroperitoneal, 800
testicular cancer after orchiectomy for, 554
Semmes-Weinstein monofilaments, 1145
Serum acid phosphatase, 707
Shock wave lithotripsy, fishnet gantry for, 795
Signal transduction modulators, 4A-77
Sildenafil citrate
alpha-adrenergic receptor antagonists and, 585
efficacy and safety of, 1141
patient and partner satisfaction assessments, 960
penile hemodynamic evaluations using, 623
sexual dysfunction treated with, 769
side effects of, 1141
Sling surgery
prevalence of, 45
suburethral placement of, 49
Sperm, testicular extraction of, 334, 365
SRD5A2, V89L polymorphism of, 199
Staphylococcus saprophyticus, urinary tract infections caused by, 17
Stents
prostatic removal of, 166
ureteral
after ureteroscopy, 639

bedside, 1163
urine leak after partial nephrectomy treated using, 355
Stress incontinence
calcium hydroxylapatite as transurethral bulking agents for, 434
sling surgery
pelvic organ prolapse surgery concomitantly performed, 911
prevalence of, 45
suburethral placement of, 49
vaginal reconstruction surgery concomitantly performed, 911
vaginal vault prolapse associated with, 40
Submucosal graft, for tunica albuginea closure in Peyronie's disease patients, 753
Supersonic transporter deformity, 1160
Sural nerve grafting, during radical prostatectomy
description of, 211
harvesting techniques, 921
necessity evaluations, 1020
rationale for, 1016

Tamoxifen with vinblastine and 5-fluorouracil, for renal cell carcinoma, 650
Tamsulosin, 466
Telomerase activation, in prostate cancer, 4A-148
Terazosin, 66
Testes
microlithiasis of, 1133
testicular sperm extraction effects, 334
torsion of, 783
Testicular cancer
after orchiectomy for seminoma, 554
chemotherapy, 555
familial influences, 747
incidence studies, 747
residual masses, surgical resection of, 323
Testicular sperm extraction, 334, 365
Thermoablation
prostate tissue, 78
radiofrequency energy for, 78
Thermotherapy. *See* Transurethral microwave thermotherapy
Three-dimensional conformal radiation therapy, 102, 769, 955
Tolterodine, overactive bladder treated with, 414
Topiglan, 301
Transitional cell carcinoma. *See also* Bladder cancer
5-aminolevulinic acid-induced fluorescence endoscopic detection of, 690, 1059
angiogenesis effects, 895, 981
biomarkers for diagnosing, 847, 849
carcinoma in situ, 60
cellular proliferation and apoptosis in, 981
gene therapy for, 579
nephroureterectomy, laparoscopic, 448
p53 gene mutations in, 852
recurrence, angiogenesis for predicting, 895
Transition zone biopsy, 1117
Transition zone index, 524
Transperitoneal laparoscopic nephrectomy, 360
Transrectal ultrasonography
for assessing prostate volume obtained by digital rectal examination, 1087
characteristics of, 4A-121
chemopreventive uses of, 4A-121
Transurethral bulking agents, 434
Transurethral microwave thermotherapy
alpha-blockade vs., 66
benign prostatic hyperplasia treated using, 701
Transurethral resection of the prostate gland
holmium laser resection vs., 454
irrigation fluid temperature effects on core body temperature during, 1078
medical therapy effects on need for, 1082
prostate-specific antigen detection vs., in well-differentiated prostate cancer, 733
voiding difficulties after, 270
Transvaginal sacrospinous colpopexy, 666
Tuberculosis, prostate, 872
Tunica albuginea, submucosal graft for closure of, 753
Tyrosine kinase inhibitors, 4A-77

Ultrasonography
prostate cancer evaluations using
detection, 1128
staging, 914
prostatic utricle associated with hypospadias evaluated using, 1151
three-dimensional vs. two-dimensional, 914
transrectal
for assessing prostate volume obtained by digital rectal examination, 1087
characteristics of, 4A-121
chemopreventive uses of, 4A-121
Upper pole moiety, 1178
Ureter
calculi formation in, 800
replacement of, 1038, 1156
stenosis of, 1038
stenting of, 639, 1163
uretero-intestinal anastomosis, 234
Ureteral-pouch stricture, 800
Ureterocele, 1178
Ureterocele prolapse, 554
Uretero-intestinal anastomosis, 234
Ureteroneocystostomy, extravesical seromuscular tunnel, 1055
Ureteropelvic junction obstruction
calculus formation, 168, 542
crossing vessels, 338
hydronephrosis secondary to, 1178
in pediatric patients, 338, 542, 547
percutaneous nephrostomy for, 547
treatment of, 338
Ureteroscopy, ureteral stent placement after, 639
Urethra
atrophy of, nocturnal deactivation of artificial urinary sphincter effects on, 1051
bacteriostatic lubricants, effect on bacille Calmette-Guérin therapy, 900
diverticula of, 660
endoscopic realignment for traumatic injuries of, 439, 628
posterior valves, postbirth presentation of, 1178
prostatic utricle, retrograde urethrography and ultrasonography evaluations of, 1151
pubovaginal sling-induced erosion of, 159
strictures of, 169
Urethrocutaneous fistula, 347
Urinary flow, endoscopic laser papillectomy effects on, 832
Urinary frequency, daytime syndrome of, 791
Urinary tract
fibrin glue for wound closure in, 806
2-octyl cyanoacrylate adhesive for wound closure in, 806
smooth muscle of, muscle-derived cell transplantation in, 826
Urinary tract infections
cranberry juice for, 26, 407

diagnostic workup evaluations, 1068
Escherichia coli, 556
host and pathogen interactions in, 6A-56
recurrent, 1068
Staphylococcus saprophyticus in, 17
Urine
female, prostate-specific antigen in, 717
growth factors, 371
interstitial cystitis markers in, 6A-9, 6A-15
matrix metalloproteinases excretion in, 675
postvoid residual, 459, 1093
Urodynamic patterns, 239, 270
Urosepsis, 554
Urothelial cell carcinoma. *See also* Bladder cancer
familial, karyotype abnormalities in, 266
nephroureterectomy for, 133

Vagina
reconstruction of, during surgery for stress incontinence, 911
vault prolapse, 40, 666
Vaginal epithelium, *Escherichia coli* adherence to, 556
Varicocele
in oligospermic men, 530
in pediatric patients, 154
surgical repair of, 328
Varicocelectomy, in oligospermic men, 530
Vascular endothelial growth factor, prostate cancer expression of, 821
Vesicoureteral reflux, cystoscopy before surgical repair of, 1156
Vesicovaginal fistula, 670
Viagra. *See* Sildenafil citrate
Vinblastine with tamoxifen and 5-fluorouracil, for renal cell carcinoma, 650
Vitamin A metabolites, 4A-81
Vitamin D analogs, 4A-81
Vitamin E, 4A-90
Voiding, transurethral resection of the prostate gland effects, 270
Voiding cystourethrography, magnetic resonance imaging vs., 660
Voiding dysfunction, multiple sclerosis patients, 239
Vulva, Semmes-Weinstein monofilaments for evaluating pressure/touch sensitivity of, 1145

Women
bladder endometriosis, 798
continence complex neuroanatomy studies in, 382
prostate-specific antigen in urine of, 717
prune-belly syndrome, 975, 1178
sexual arousal response in, 1189
urethral diverticula in, 660
urinary tract infections. *See* Urinary tract infections
vulvar sensitivity to pressure/touch, Semmes-Weinstein monofilaments for evaluating, 1145

Xanthogranulomatous pyelonephritis, 168